Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mwangi J Murage, Vanita Tongbram, Steven R Feldman, William N Malatestinic, Cynthia J Larmore, Talia M Muram, Russel T Burge, Charles Bay, Nicole Johnson, Sarah Clifford & Andre B Araujo. (2018) Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Preference and Adherence 12, pages 1483-1503.
Read now
Read now
Ning Wu, Sharvari Bhurke, Neel Shah & David J Harrison. (2015) Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context. ClinicoEconomics and Outcomes Research 7, pages 257-266.
Read now
Read now
Vasilis Fragoulakis, Elli Vitsou, Ana Cristina Hernandez & Nikolaos Maniadakis. (2015) Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece. ClinicoEconomics and Outcomes Research 7, pages 85-93.
Read now
Read now
Diego Sangiorgi, Maurizio Benucci, Carmela Nappi, Valentina Perrone, Stefano Buda & Luca Degli Esposti. (2015) Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis. Biologics: Targets and Therapy 9, pages 119-127.
Read now
Read now
Joaquín Borrás-Blasco & Andres Navarro Ruiz. (2015) Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies. Expert Review of Pharmacoeconomics & Outcomes Research 15:1, pages 71-79.
Read now
Read now
Articles from other publishers (17)
Fiorenzo Santoleri, Ruggero Lasala, Paolo Abrate, Laura Pestrin, Enrico Pasut, Germana Modesti, Felice Musicco, Chiara Fulgenzio, Eva Zuzolo, Gabriella Pieri, Martina Roperti, Pietro Gazzola, Marco GamberaIsabella MartignoniValentina MontresorFrancesco De Vita, Francesca Guarino, Laura Grossi, Letizia Di Fabio, Cristina Roberti, Concetta Spoltore, Gabriella Tinari, Stefania De Rosa, Romina Giannini, Roberto Langella, Grazia Mingolla, Mariantonietta Piccoli & Alberto Costantini. (2023) ADA_ETA_BIO2021: real-world evaluation of adherence, persistence, and cost-effectiveness of originator and biosimilar biologic drugs in the treatment of rheumatoid arthritis: a multicenter study in Italy. Current Medical Research and Opinion, pages 1-13.
Crossref
Crossref
Kelly C. BroderickJames P. BurkeJesse FishmanPatrick P. Gleason. (2023) Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuria. Journal of Managed Care & Specialty Pharmacy 29:8, pages 941-951.
Crossref
Crossref
Vandana Bhushan, Susan Lester, Liz Briggs, Raif Hijjawi, E. Michael Shanahan, Eliza Pontifex, Jem Ninan, Catherine Hill, Fin Cai, Jennifer Walker, Fiona Goldblatt & Mihir D. Wechalekar. (2021) Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Frontiers in Medicine 8.
Crossref
Crossref
Silje W Syversen, Guro L Goll, Kristin K Jørgensen, Inge C Olsen, Øystein Sandanger, Johanna E Gehin, David J Warren, Joseph Sexton, Cato Mørk, Jørgen Jahnsen, Tore K Kvien, Nils Bolstad & Espen A Haavardsholm. (2020) Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study). Trials 21:1.
Crossref
Crossref
Rituparna BhattacharyaKatie HerrenInsiya PoonawallaSuvapun BunniranAndrea BloomfieldPhil Schwab. (2020) Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases. Journal of Managed Care & Specialty Pharmacy 26:10, pages 1246-1256.
Crossref
Crossref
Stanley B. Cohen, Joel M. Kremer, Kimberly J. Dandreo, George W. Reed, Robert Magner, Ying Shan, Shelly Kafka, Raphael J. DeHoratius, Lorie Ellis & Dennis Parenti. (2019) Outcomes of infliximab dose escalation in patients with rheumatoid arthritis. Clinical Rheumatology 38:9, pages 2501-2508.
Crossref
Crossref
Nikos Maniadakis, Emese Toth, Michael Schiff, Xuan Wang, Maria Nassim, Boglarka Szegvari, Irina Mountian & Jeffrey R. Curtis. (2018) A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences. Advances in Therapy 35:9, pages 1333-1355.
Crossref
Crossref
Thomas Wilke, Sabrina Mueller, Sze Chim Lee, Istvan Majer & Marieke Heisen. (2017) Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis. BMC Musculoskeletal Disorders 18:1.
Crossref
Crossref
Carter Thorne, Gilles Boire, Andrew Chow, Kirsten Garces, Fang Liu, Melanie Poulin-Costello, Valery Walker & Boulos Haraoui. (2017) Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study. The Open Rheumatology Journal 11:1, pages 123-135.
Crossref
Crossref
Paolo Faccendini, Enrica Cantillo, Caterina Fanizza & Maria Grazia Celeste. (2017) Analisi di Farmacoutilizzazione dei Trattamenti Biologici Nelle Malattie Infiammatorie Immunomediate Croniche: I Risultati di Uno Studio Osservazionale Retrospettivo Condotto in un Centro Ospedaliero del Centro Italia. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 4:1, pages grhta.5000271.
Crossref
Crossref
Mark C. Genovese, Ronald F. van Vollenhoven, Bethanie Wilkinson, Lisy Wang, Samuel H. Zwillich, David Gruben, Pinaki Biswas, Richard Riese, Liza Takiya & Thomas V. Jones. (2016) Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. Arthritis Research & Therapy 18:1.
Crossref
Crossref
Gundula Krack, Henning Zeidler & Jan Zeidler. (2016) Claims Data Analysis of Tumor Necrosis Factor Inhibitor Treatment Dosing Among Patients with Rheumatoid Arthritis: A Systematic Review of Methods. Drugs - Real World Outcomes 3:3, pages 265-278.
Crossref
Crossref
Grant W. Cannon, Scott L. DuVall, Candace L. Haroldsen, Liron Caplan, Jeffrey R. Curtis, Kaleb Michaud, Ted R. Mikuls, Andreas Reimold, David H. Collier, George J. Joseph, David J. Harrison & Brian C. Sauer. (2016) Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. Advances in Therapy 33:8, pages 1347-1359.
Crossref
Crossref
Rafael Ferriols-Lisart & Francisco Ferriols-Lisart. (2015) Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review. Rheumatology International 35:7, pages 1193-1210.
Crossref
Crossref
Sarah Neubauer, Mary Cifaldi, Thomas Mittendorf, Arijit Ganguli, Malte Wolff & Jan Zeidler. (2014) Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany. Health Economics Review 4:1.
Crossref
Crossref
Ling Ling Zhang, Sen Yang, Wei Wei & Xue Jun Zhang. (2014) Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis. Pharmacogenetics and Genomics 24:11, pages 531-538.
Crossref
Crossref
Grant W. Cannon, Scott L. DuVall, Candace L. Haroldsen, Liron Caplan, Jeffrey R. Curtis, Kaleb Michaud, Ted R. Mikuls, Andreas Reimold, David H. Collier, David J. Harrison, George J. Joseph & Brian C. Sauer. (2014) Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. The Journal of Rheumatology 41:10, pages 1935-1943.
Crossref
Crossref